Article
Transgenic expression of bean alpha-amylase inhibitor in peas results in altered structure and immunogenicity.
Division of Molecular Bioscience, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.
Journal of Agricultural and Food Chemistry (impact factor:
2.82).
12/2005;
53(23):9023-30.
DOI:10.1021/jf050594v
Source: PubMed
-
Article: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants.
[show abstract] [hide abstract]
ABSTRACT: The use of plants for medicinal purposes dates back thousands of years but genetic engineering of plants to produce desired biopharmaceuticals is much more recent. As the demand for biopharmaceuticals is expected to increase, it would be wise to ensure that they will be available in significantly larger amounts, on a cost-effective basis. Currently, the cost of biopharmaceuticals limits their availability. Plant-derived biopharmaceuticals are cheap to produce and store, easy to scale up for mass production, and safer than those derived from animals. Here, we discuss recent developments in this field and possible environmental concerns.Trends in Plant Science 06/2001; 6(5):219-26. · 11.05 Impact Factor -
Article: Overview of the current status of genetically modified plants in Europe as compared to the USA.
[show abstract] [hide abstract]
ABSTRACT: Genetically modified crops have been tested in 1,726 experimental releases in the EU member states and in 7,815 experimental releases in the USA. The global commercial cultivation area of genetically modified crops is likely to reach 50 million hectares in 2001, however, the commercial production of genetically modified crops in the EU amounts to only a few thousand hectares and accounts for only some 0.03% of the world production. A significant gap exists between the more than fifty genetically modified crop species already permitted to be cultivated and to be placed on the market in the USA, Canada and other countries and the five genetically modified crop species permitted for the same use in the EU member states, which are still pending inclusion in the Common Catalogue of agricultural plant species. The further development of the "green gene technology" in the EU will be a matter of public acceptance and administrative legislation.Journal of Plant Physiology 08/2003; 160(7):735-42. · 2.79 Impact Factor -
Article: Enhanced methionine levels and increased nutritive value of seeds of transgenic lupins (Lupinus angustifolius L.) expressing a sunflower seed albumin gene.
[show abstract] [hide abstract]
ABSTRACT: With the aim of improving the nutritive value of an important grain legume crop, a chimeric gene specifying seed-specific expression of a sulfur-rich, sunflower seed albumin was stably transformed into narrow-leafed lupin (Lupinus angustifolius L.). Sunflower seed albumin accounted for 5% of extractable seed protein in a line containing a single tandem insertion of the transferred DNA. The transgenic seeds contained less sulfate and more total amino acid sulfur than the nontransgenic parent line. This was associated with a 94% increase in methionine content and a 12% reduction in cysteine content. There was no statistically significant change in other amino acids or in total nitrogen or total sulfur contents of the seeds. In feeding trials with rats, the transgenic seeds gave statistically significant increases in live weight gain, true protein digestibility, biological value, and net protein utilization, compared with wild-type seeds. These findings demonstrate the feasibility of using genetic engineering to improve the nutritive value of grain crops.Proceedings of the National Academy of Sciences 09/1997; 94(16):8393-8. · 9.68 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
alpha-amylase inhibitor-1
antigen-specific CD4+ Th2-type inflammation
discrete changes
elicited specific immunoreactivity
heterogeneous proteins
modern gene technologies
modified alphaAI
modified alphaAI concurrently
molecular architecture
native form predisposed
non-native host
non-native hosts
non-native proteins
Phaseolus vulgaris L. cv
Pisum sativum L
post-translational modification pathways
recombinant proteins
subsequent cellular function
transgenic expression
transgenic pea